Alpine Woods Capital Investors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $442K | Buy |
+3,500
| New | +$461K | 0.1% | 133 |
|
|
2022
Q4 | – | Sell |
-5,200
| Closed | -$321K | – | 189 |
|
|
2022
Q3 | $321K | Hold |
5,200
| – | – | 0.04% | 168 |
|
|
2022
Q2 | $321K | Hold |
5,200
| – | – | 0.04% | 174 |
|
|
2022
Q1 | $309K | Hold |
5,200
| – | – | 0.03% | 193 |
|
|
2021
Q4 | $378K | Hold |
5,200
| – | – | 0.04% | 185 |
|
|
2021
Q3 | $363K | Hold |
5,200
| – | – | 0.04% | 193 |
|
|
2021
Q2 | $358K | Sell |
5,200
-400
| -7% | -$26.7K | 0.04% | 201 |
|
|
2021
Q1 | $362K | Sell |
5,600
-200
| -3% | -$12.9K | 0.04% | 200 |
|
|
2020
Q4 | $338K | Sell |
5,800
-100,571
| -95% | -$6.07M | 0.04% | 198 |
|
|
2020
Q3 | $6.72M | Buy |
106,371
+57,184
| +116% | +$3.97M | 1.02% | 24 |
|
|
2020
Q2 | $3.78M | Buy |
49,187
+6,887
| +16% | +$528K | 0.73% | 40 |
|
|
2020
Q1 | $3.16M | Buy |
42,300
+26,444
| +167% | +$1.83M | 0.7% | 32 |
|
|
2019
Q4 | $1.03M | Buy |
15,856
+12,500
| +372% | +$814K | 0.2% | 110 |
|
|
2019
Q3 | $213K | Buy |
3,356
+356
| +12% | +$23.3K | 0.04% | 240 |
|
|
2019
Q2 | $203K | Sell |
3,000
-500
| -14% | -$32.9K | 0.04% | 260 |
|
|
2019
Q1 | $228K | Sell |
3,500
-100
| -3% | -$6.65K | 0.05% | 232 |
|
|
2018
Q4 | $225K | Sell |
3,600
-1,200
| -25% | -$83.9K | 0.05% | 235 |
|
|
2018
Q3 | $371K | Buy |
4,800
+500
| +12% | +$37.8K | 0.08% | 174 |
|
|
2018
Q2 | $305K | Hold |
4,300
| – | – | 0.07% | 178 |
|
|
2018
Q1 | $324K | Sell |
4,300
-1,300
| -23% | -$103K | 0.02% | 329 |
|
|
2017
Q4 | $401K | Sell |
5,600
-10,000
| -64% | -$759K | 0.02% | 335 |
|
|
2017
Q3 | $1.26M | Hold |
15,600
| – | – | 0.06% | 230 |
|
|
2017
Q2 | $1.1M | Hold |
15,600
| – | – | 0.06% | 234 |
|
|
2017
Q1 | $1.06M | Sell |
15,600
-16,000
| -51% | -$1.13M | 0.06% | 244 |
|
|
2016
Q4 | $2.26M | Sell |
31,600
-1,100
| -3% | -$81.8K | 0.13% | 168 |
|
|
2016
Q3 | $2.59M | Sell |
32,700
-66,700
| -67% | -$5.42M | 0.14% | 157 |
|
|
2016
Q2 | $8.29M | Buy |
99,400
+2,500
| +3% | +$222K | 0.5% | 72 |
|
|
2016
Q1 | $8.9M | Buy |
96,900
+25,700
| +36% | +$2.32M | 0.52% | 70 |
|
|
2015
Q4 | $7.21M | Sell |
71,200
-18,500
| -21% | -$1.92M | 0.39% | 85 |
|
|
2015
Q3 | $8.81M | Buy |
89,700
+27,000
| +43% | +$3M | 0.48% | 69 |
|
|
2015
Q2 | $7.34M | Sell |
62,700
-1,000
| -2% | -$109K | 0.38% | 94 |
|
|
2015
Q1 | $6.25M | Buy |
63,700
+40,000
| +169% | +$4.06M | 0.32% | 96 |
|
|
2014
Q4 | $2.23M | Buy |
23,700
+6,000
| +34% | +$621K | 0.11% | 168 |
|
|
2014
Q3 | $1.88M | Buy |
17,700
+9,400
| +113% | +$920K | 0.1% | 182 |
|
|
2014
Q2 | $688 | Hold |
8,300
| – | – | 0.02% | 277 |
|
|
2014
Q1 | $588K | Buy |
+8,300
| New | +$651K | 0.03% | 287 |
|
Other funds holding GILD
Alpine Woods Capital Investors's GILD Position: Q2 2026 in Review
Alpine Woods Capital Investors opened a new position in Gilead Sciences (GILD) in Q2 2026: 3,500 shares worth $442K. The stake represents 0.1% of the portfolio and ranks #133 among its holdings. This is a return to the name: Alpine Woods Capital Investors previously reported a position in GILD as recently as Q3 2022.
Alpine Woods Capital Investors first reported a position in GILD in Q1 2014 and has held it in 36 quarters since. The position peaked at $8.9M in Q1 2016. 1,412 funds tracked by Wall St. Rank hold GILD as of Q2 2026.
- Alpine Woods Capital Investors held 3,500 shares of Gilead Sciences worth $442K as of Q2 2026.
- Gilead Sciences was a new Alpine Woods Capital Investors position in Q2 2026.
- Gilead Sciences made up 0.1% of Alpine Woods Capital Investors's portfolio in Q2 2026, its #133 holding.
- Alpine Woods Capital Investors first reported a position in Gilead Sciences in Q1 2014 and has held it in 36 quarters since.
- Alpine Woods Capital Investors's Gilead Sciences position peaked at $8.9M in Q1 2016.
- 1,412 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.
Based on Alpine Woods Capital Investors's 13F filing for Q2 2026, filed 7 Aug 2026.